Dosing & Uses
Dosage Forms & Strengths
IV solution
- 20mg/mL
- 40mg/2mL
Peripheral T-Cell Lymphoma
Indicated for relapsed or refractory PTCL
30 mg/m² IV qweek for 6 week in 7 week cycles
Dosage modifications
- Before administering any pralatrexate dose, mucositis should be ≤Grade 1, platelet count should be ≥100,000/mcL (first dose) and ≥50,000/mcL (subsequent doses), and absolute neutrophil count (ANC) should be ≥1,000/mcL
- See Prescribing Information for omitting or reducing dose based on patient tolerance
- Omitted doses will not be made up at the end of the cycle
- Once dose reduction occurs for toxicity, do not re-escalate
Renal Impairment
eGFR ≥ 30 mL/min/1.73 m²: Dose adjustment not necessary
Estimated GFR (eGFR) 15 to <30 mL/min/1.73 m²: Reduce initial dose to 15 mg/m²; if dose reduction necessary because of toxicity, reduce each dose to 10 mg/m²
End-stage renal disease (ESRD): Avoid use unless potential benefits outweigh risks
Hepatic Impairment
Grade 3 (AST or ALT >5 to 20 times ULN or bilirubin >3 to 10 times ULN): Omit dose; decrease to 20 mg/m m² when recovers to grade 2
Grade 4 (AST or ALT >20 times ULN or bilirubin >10 times ULN): Discontinue treatment
Orphan Indications
Diffuse large B-cell lymphoma
Advanced or metastatic transitional cell urinary bladder carcinoma
Follicular lymphoma
Orphan indications sponsor
- Allos Therapeutics, Inc; 11080 CirclePoint Road; Westminster, CO
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (11)
- adenovirus types 4 and 7 live, oral
pralatrexate decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.
- axicabtagene ciloleucel
pralatrexate, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- brexucabtagene autoleucel
pralatrexate, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- ciltacabtagene autoleucel
pralatrexate, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- idecabtagene vicleucel
pralatrexate, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- influenza virus vaccine quadrivalent, adjuvanted
pralatrexate decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.
- influenza virus vaccine trivalent, adjuvanted
pralatrexate decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.
- lisocabtagene maraleucel
pralatrexate, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- palifermin
palifermin increases toxicity of pralatrexate by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.
- tisagenlecleucel
pralatrexate, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- tofacitinib
pralatrexate, tofacitinib. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
Monitor Closely (44)
- aspirin rectal
aspirin rectal increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- belatacept
belatacept and pralatrexate both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.
- celecoxib
celecoxib increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- cholera vaccine
pralatrexate decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.
- choline magnesium trisalicylate
choline magnesium trisalicylate increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- dengue vaccine
pralatrexate decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.
- denosumab
pralatrexate, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
- dichlorphenamide
dichlorphenamide and pralatrexate both decrease serum potassium. Use Caution/Monitor.
- diclofenac
diclofenac increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- diflunisal
diflunisal increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- etodolac
etodolac increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- fenoprofen
fenoprofen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- fingolimod
pralatrexate increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .
- flurbiprofen
flurbiprofen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- glucarpidase
glucarpidase will decrease the level or effect of pralatrexate by increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)
- hydroxyurea
pralatrexate, hydroxyurea. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of myelosuppression.
- ibuprofen
ibuprofen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- ibuprofen IV
ibuprofen IV increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- indomethacin
indomethacin increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- influenza A (H5N1) vaccine
pralatrexate decreases effects of influenza A (H5N1) vaccine by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine.
- influenza virus vaccine (H5N1), adjuvanted
pralatrexate decreases effects of influenza virus vaccine (H5N1), adjuvanted by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine.
- ketoprofen
ketoprofen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- ketorolac
ketorolac increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- ketorolac intranasal
ketorolac intranasal increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- meclofenamate
meclofenamate increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- mefenamic acid
mefenamic acid increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- meloxicam
meloxicam increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- meningococcal group B vaccine
pralatrexate decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.
- nabumetone
nabumetone increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- naproxen
naproxen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- ofatumumab SC
ofatumumab SC, pralatrexate. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.
- olaparib
pralatrexate and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity.
- oxaprozin
oxaprozin increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- piroxicam
piroxicam increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- probenecid
probenecid increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- siponimod
siponimod and pralatrexate both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.
- sipuleucel-T
pralatrexate decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.
- sulfamethoxazole
sulfamethoxazole increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- sulindac
sulindac increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- tolmetin
tolmetin increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
- trastuzumab
trastuzumab, pralatrexate. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy.
- trastuzumab deruxtecan
trastuzumab deruxtecan, pralatrexate. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy.
- ublituximab
ublituximab and pralatrexate both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered
Minor (4)
- maitake
maitake increases effects of pralatrexate by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).
- taurine
pralatrexate decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- vitamin A
vitamin A, pralatrexate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs.
- vitamin E
vitamin E, pralatrexate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs.
Adverse Effects
>10%
Inflammatory disease of mucous membrane, Any grade (70% )
Thrombocytopenia, Any grade (41% )
Nausea (40% )
Fatigue (36% )
Anemia, Any grade (34% )
Constipation (33% )
Pancytopenia, Thrombocytopenia, Grade 3/4 (33% )
Edema (30% )
Cough (28% )
Neutropenia, Any grade (24% )
Inflammatory disease of mucous membrane, Grade 3/4 (21% )
Neutropenia, Grade 3/4 (20% )
Dyspnea (19% )
Anemia (17% )
1-10%
Febrile neutropenia (>3% )
Sepsis (>3% )
Postmarketing Reports
Skin exfoliation, ulceration, and toxic epidermal necrolysis
Warnings
Contraindications
Hypersensitivity
Cautions
Treatment can cause mucositis; administer vitamin B12 and instruct patients to take folic acid to reduce risk of mucositis; monitor for mucositis weekly and omit and/or reduce dose for grade 2 or higher mucositis
Treatment interruption or dose reduction to 20 mg/sq.meter may be required with severe mucositis, thrombocytopenia, or elevated liver function tests
Caution with moderate-to-severe renal impairment (higher risk for toxicity); monitor for systemic toxicity and adjust dose accordingly
Reports of severe dermatologic reactions including skin exfoliation, ulceration, and toxic epidermal necrolysis; reactions may be progressive and increase in severity with further treatment and may involve skin and subcutaneous sites of known lymphoma; monitor closely for dermatologic reactions (withhold or discontinue treatment)
Treatment can cause tumor lysis syndrome (TLS); monitor patients who are at increased risk of TLS and treat promptly
Avoid breastfeeding
Probenecid decreases renal elimination of pralatrexate
Myelosuppression
- Therapy can cause myelosuppression, manifested by thrombocytopenia, neutropenia, and/or anemia
- Administer vitamin B12 and instruct patients to take folic acid to reduce the risk of treatment-related myelosuppression
- Monitor complete blood counts and omit and/or reduce the dose based on ANC and platelet count prior to each dose
Hepatotoxicity
- Can cause hepatic toxicity and liver function test abnormalities; persistent liver function test abnormalities may be indicators of hepatic toxicity and require dose modification or discontinuation.
- Monitor liver function tests. Omit dose until recovery, adjust or discontinue therapy based on the severity of the hepatic toxicity
Renal Impairment
- Patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2 based on MDRD) may be at greater risk for increased exposure and adverse reactions; reduce dosage in patients with severe renal impairment
- Serious adverse reactions, including TEN and mucositis, reported in patients receiving therapy with end-stage renal disease (ESRD) undergoing dialysis; avoid therapy in patients with ESRD with or without dialysis; If the potential benefit of administration justifies the potential risk, monitor renal function and reduce dose based on adverse reactions
Pregnancy & Lactation
Pregnancy
Based on findings from animal studies and mechanism of action therapy can cause fetal harm when administered to a pregnant woman; there are insufficient data on use in pregnant women to evaluate for a drug-associated risk; drug was embryotoxic and fetotoxic in rats and rabbits when administered during organogenesis at doses about 1.2% (0.012 times) of clinical dose on a mg/m2 basis; advise pregnant women of potential risk to a fetus
Therapy can cause fetal harm when administered to a pregnant woman; verify pregnancy status in females of reproductive potential prior to initiation of therapy
Contraception
- Females: Advise females of reproductive potential to use effective contraception during treatment and for 6 months following last dose
- Males: Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months following last dose
Lactation
There is no data on presence in human milk or effects on breastfed child or milk production; because of potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 week after last dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Folate inhibitor
Pharmacokinetics
Clearance: 417 mL/min (S-diastereomer); 191 mL/min (R-diastereomer)
Half-life: 12-18 hr
Vd: 105 L (S-diastereomer); 37 L (R-diastereomer)
Protein Bound: 67%
Metabolism: Not significantly metabolized by CYP450 or hepatic glucuronidases
Excretion: (urine) 34% unchanged
Administration
IV Preparation
Do not dilute
Contains no preservatives
Clear, yellow solution; inspect for discoloration/particulate matter
IV Administration
Infuse IV over 3-5 minute via side port of free-flowing 0.9% NaCl IV line
Dose omissions and/or dose reductions may be needed to manage adverse drug reactions
Pretreatment vitamin supplementation
- Folic acid: Initiate 1-1.25 mg PO qDay 10 days before first pralatrexate dose; continue daily folic acid during entire treatment course and for 30 days after last pralatrexate dose
- Vitamin B12: 1 mg IM within 10 weeks before first pralatrexate dose and q8-10 wk thereafter
Extravasation Management
Terminate injection or infusion immediately & aspirate back as much as possible
Apply warm pack for 15-20 min QID & elevate
Storage
Store intact vials under refrigeration at 2-8°C
Store in original carton to protect from light
Intact, unopened vials stable at room temperature for 72 hr if protected from light (discard after 72 hr)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Folotyn intravenous - | 40 mg/2 mL (20 mg/mL) vial |  | |
| Folotyn intravenous - | 20 mg/mL (1 mL) vial |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
